NCT02355743View on ClinicalTrials.gov

rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 1, 2015

Primary Completion Date

September 3, 2016

Study Completion Date

September 3, 2016

Conditions
Short Bowel Syndrome
Interventions
DRUG

rtPA lock therapy

"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."

Trial Locations (1)

15224

Children's Hospital of Pittsburgh, Pittsburgh

All Listed Sponsors
collaborator

University of Pittsburgh

OTHER

lead

Lynn Malec

OTHER

NCT02355743 - rtPA in in the Prevention of CVAD-Associated Thrombosis and Infection in Pediatric Patients With Short Bowel Syndrome | Biotech Hunter | Biotech Hunter